Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

BACKGROUND: Anti–IL-5 therapy is a potential treatment for patients with hypereosinophilic syndrome (HES), although its clinical efficacy is unclear. OBJECTIVE: We sought to investigate the clinical efficacy and safety of mepolizumab versus placebo in patients with HES. METHODS: This randomized, mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Roufosse, Florence, Kahn, Jean-Emmanuel, Rothenberg, Marc E., Wardlaw, Andrew J., Klion, Amy D., Kirby, Suyong Yun, Gilson, Martyn J., Bentley, Jane H., Bradford, Eric S., Yancey, Steven W., Steinfeld, Jonathan, Gleich, Gerald J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579892/
https://www.ncbi.nlm.nih.gov/pubmed/32956756
http://dx.doi.org/10.1016/j.jaci.2020.08.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579892/
https://www.ncbi.nlm.nih.gov/pubmed/32956756
http://dx.doi.org/10.1016/j.jaci.2020.08.037

Ejemplares similares